{'fraction_non_alphanumeric': 0.019639934533551555, 'fraction_numerical': 0.0, 'mean_word_length': 5.181818181818182, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunotherapy for multiple sclerosis.

Multiple sclerosis ought to be one of the more easily curable neurological diseases. The damage is targeted on myelin rather than axons. It affects the young rather than the old. It causes inflammation rather than degeneration. It involves environmental, and not just genetic, aetiological factors. Recent advances in trial methodology, the availability of MRI scans as a surrogate marker, and the appearance of novel immunomodulatory agents bring worthwhile treatment a step nearer. The time is ripe to review how far recent trials should influence neurological practice.